Acuitas Therapeutics
Acuitas Therapeutics is a Vancouver-based biotechnology company focused on enabling nucleic acid therapeutics through lipid nanoparticle (LNP) delivery systems. The company provides LNP research, formulation, analytical, preclinical and process-development capabilities to partners, and supports translation from preclinical optimization to clinical trials, regulatory submissions and manufacturing scale-up.
Industries
Nr. of Employees
small (1-50)
Acuitas Therapeutics
6190 Agronomy Road, Suite 205, Vancouver, BC, V6T 1Z3, Canada
Patents
Products
Lipid Nanoparticle (LNP) Delivery Technology
A delivery system using lipid nanoparticles to transport nucleic acid therapeutics safely and effectively into target cells.
Novel Lipid Chemistry and Ionizable Lipid Design
Design and synthesis of novel ionizable lipids that form the core components of LNPs to improve potency and safety of nucleic acid delivery.
Formulation Development for LNP Therapeutics
Development of lipid nanoparticle formulations tailored to efficiently encapsulate nucleic acid payloads and meet specific biophysical and clinical requirements.
Analytical Characterization of LNP Therapeutics
Analytical services to characterize and assess the quality of nucleic acid-LNP formulations using advanced techniques.
Preclinical Evaluation of LNP Systems
Design and execution of in vivo studies to assess the safety and biological behavior of LNP formulations, primarily using non-human primate models.
Process Development and Technology Transfer
Development and scale-up of manufacturing processes for LNP therapeutics and transfer of these processes to partners or contract manufacturing organizations.
Lipid Nanoparticle (LNP) Delivery Technology
A delivery system using lipid nanoparticles to transport nucleic acid therapeutics safely and effectively into target cells.
Novel Lipid Chemistry and Ionizable Lipid Design
Design and synthesis of novel ionizable lipids that form the core components of LNPs to improve potency and safety of nucleic acid delivery.
Formulation Development for LNP Therapeutics
Development of lipid nanoparticle formulations tailored to efficiently encapsulate nucleic acid payloads and meet specific biophysical and clinical requirements.
Analytical Characterization of LNP Therapeutics
Analytical services to characterize and assess the quality of nucleic acid-LNP formulations using advanced techniques.
Preclinical Evaluation of LNP Systems
Design and execution of in vivo studies to assess the safety and biological behavior of LNP formulations, primarily using non-human primate models.
Process Development and Technology Transfer
Development and scale-up of manufacturing processes for LNP therapeutics and transfer of these processes to partners or contract manufacturing organizations.
Services
Technology evaluation assessment and licensing of LNP delivery systems and access to proprietary lipid materials for partner development programs.
Development of LNP formulations and analytical method development and testing to characterize product quality, payload loading and stability.
Design and execution of pharmacology, biodistribution and safety studies, including non-human primate studies, to support clinical translation.
Development of scalable manufacturing processes and coordination of technology transfer to contract manufacturers for clinical and commercial supply.
Provision and management of cGMP-grade lipid materials to support partner clinical programs.
Ongoing project coordination, partner onboarding and cross-team collaboration to manage multi-disciplinary development programs.
Technology evaluation assessment and licensing of LNP delivery systems and access to proprietary lipid materials for partner development programs.
Development of LNP formulations and analytical method development and testing to characterize product quality, payload loading and stability.
Design and execution of pharmacology, biodistribution and safety studies, including non-human primate studies, to support clinical translation.
Development of scalable manufacturing processes and coordination of technology transfer to contract manufacturers for clinical and commercial supply.
Provision and management of cGMP-grade lipid materials to support partner clinical programs.
Ongoing project coordination, partner onboarding and cross-team collaboration to manage multi-disciplinary development programs.
Expertise Areas
- Lipid nanoparticle delivery systems
- Ionizable lipid chemistry and materials development
- Formulation development for nucleic acid therapeutics
- Analytical method development for complex biologics
Key Technologies
- Lipid nanoparticle (LNP) delivery systems
- Ionizable lipid synthesis and SAR modeling
- PEGylated lipid stabilization
- mRNA, siRNA and guide RNA delivery
News & Updates
Poster presentations on mRNA-LNP base editing spatial resolution and PK/distribution of mRNA-LNP in gonadal tissues at ASGCT 2024.
Company presentations and data releases on next-generation LNP at industry conferences.
Multiple peer-reviewed publications in 2024–2025 reporting LNP-enabled vaccine and gene-editing research outcomes.
LNP formulations developed by the company have been used in clinically approved nucleic acid products.
Multiple organizational awards including national and regional industry recognitions between 2021 and 2024.
Poster presentations on mRNA-LNP base editing spatial resolution and PK/distribution of mRNA-LNP in gonadal tissues at ASGCT 2024.
Company presentations and data releases on next-generation LNP at industry conferences.
Multiple peer-reviewed publications in 2024–2025 reporting LNP-enabled vaccine and gene-editing research outcomes.
LNP formulations developed by the company have been used in clinically approved nucleic acid products.
Multiple organizational awards including national and regional industry recognitions between 2021 and 2024.